A sensitive and high-throughput assay to detect low-abundance proteins in serum

Nature Medicine

Volumn 12, Issue 4, 2006, Pages 473-477

  Zhang, Hongtao ^a   Cheng, Xin ^a   Richter, Mark ^a   Greene, Mark I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANALYTIC METHOD; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FLUORESCENT AMPLIFICATION CATALYZED BY T7 POLYMERASE TECHNIQUE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN TARGETING; RODENT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; BIOTINYLATION; BREAST NEOPLASMS; CELL LINE; DNA-DIRECTED RNA POLYMERASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; HUMANS; INJECTIONS, SUBCUTANEOUS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; RNA; SENSITIVITY AND SPECIFICITY; STREPTAVIDIN; TUMOR BURDEN; VIRAL PROTEINS;

RODENTIA;

EID: 33645748230     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1378     Document Type: Article

References (26)

1. Porstmann, T. & Kiessig, S.T. Enzyme immunoassay techniques. An overview. J. Immunol. Methods 150, 5-21 (1992).
2. Porstmann, B., Porstmann, T., Nugel, E. & Evers, U. Which of the commonly used marker enzymes gives the best results in colorimetric and fluorimetric enzyme immunoassays: horseradish peroxidase, alkaline phosphatase or beta-galactosidase? J. Immunol. Methods 79, 27-37 (1985).
3. Zhang, H.T., Kacharmina, J.E., Miyashiro, K., Greene, M.I. & Eberwine, J. Protein quantification from complex protein mixtures using a proteomics methodology with single-cell resolution. Proc. Natl. Acad. Sci. USA 98, 5497-5502 (2001).
4. Jones, L.J., Yue, S.T., Cheung, C.Y. & Singer, V.L. RNA quantitation by fluorescence-based solution assay: RiboGreen reagent characterization. Anal. Biochem. 265, 368-374 (1998).
5. Slamon, D.J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
6. Cohen, J.A. et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4, 81-88 (1989).
7. Lodato, R.F., Maguire, H.C., Jr., Greene, M.I., Weiner, D.B. & LiVolsi, V.A. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod. Pathol. 3, 449-454 (1990).
8. Maguire, H.C., Jr. & Greene, M.I. Neu (c-erbB-2), a tumor marker in carcinoma of the female breast. Pathobiology 58, 297-303 (1990).
9. Williams, T.M., Weiner, D.B., Greene, M.I. & Maguire, H.C., Jr. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 59, 46-52 (1991).
10. Jardines, L., Weiss, M., Fowble, B. & Greene, M. neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 61, 268-282 (1993).
11. Kandl, H., Seymour, L. & Bezwoda, W.R. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br. J. Cancer 70, 739-742 (1994).
12. Fehm, T., Maimonis, P., Katalinic, A. & Jager, W.H. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 55, 33-38 (1998).
13. Yamauchi, H. et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol. 15, 2518-2525 (1997).
14. Park, B.W. et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18, 194-198 (2000).
15. Di Leo, A., Dowsett, M., Horten, B. & Penault-Llorca, F. Current status of HER2 testing. Oncology 63, 25-32 (2002).
16. Vogel, C.L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
17. Saghatchian, M. et al. Serum HER-2 extracellular domain: Relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int. J. Biol. Markers 19, 14-22 (2004).
18. Luftner, D. et al. Discordant results obtained for different methods of HER-2/neu testing in breast cancer - a question of standardization, automation and timing. Int. J. Biol. Markers 19, 1-13 (2004).
19. Schweitzer, B. et al. Inaugural article: immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection. Proc. Natl. Acad. Sci. USA 97, 10113-10119 (2000).
20. Schweitzer, B. et al. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat. Biotechnol. 20, 359-365 (2002).
21. Tannous, B.A., Laios, E. & Christopoulos, T.K. T7 RNA polymerase as a self-replicating label for antigen quantification. Nucleic Acids Res. 30, e140 (2002).
22. Arnold, S. et al. Kinetic modeling and simulation of in vitro transcription by phage T7 RNA polymerase. Biotechnol. Bioeng. 72, 548-561 (2001).
23. Nam, J.M., Thaxton, C.S. & Mirkin, C.A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884-1886 (2003).
24. Lubec, G., Krapfenbauer, K. & Fountoulakis, M. Proteomics in brain research: potentials and limitations. Prog. Neurobiol. 69, 193-211 (2003).
25. Li, P., Li, Y., Li, J.Y. & Liu, J. Characterization and utilization of two novel anti-erbB-2 monoclonal antibodies in detection of soluble ErbB-2 for breast cancer prognosis. Cancer Lett. 193, 139-148 (2003).
26. Zhang, H. et al. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp. Mol. Pathol. 67, 15-25 (1999).